Factor IX Padua for haemophilia B gene addition: universal adaptation and repeated success.
作者信息
George Lindsey A
机构信息
Department of Pediatrics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA; Division of Hematology and Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.
出版信息
Lancet Haematol. 2022 Jul;9(7):e465-e466. doi: 10.1016/S2352-3026(22)00178-8.
Abstract
摘要
相似文献
1
Factor IX Padua for haemophilia B gene addition: universal adaptation and repeated success.
Lancet Haematol. 2022 Jul;9(7):e465-e466. doi: 10.1016/S2352-3026(22)00178-8.
2
A golden age for Haemophilia treatment?
Haemophilia. 2018 Mar;24(2):175-176. doi: 10.1111/hae.13411.
3
Recent advances in developing specific therapies for haemophilia.
Br J Haematol. 2018 Apr;181(2):161-172. doi: 10.1111/bjh.15084. Epub 2018 Jan 23.
4
Status of gene transfer for hemophilia A and B.
Thromb Haemost. 1991 Jul 12;66(1):119-22.
5
Key issues in inhibitor management in patients with haemophilia.
Blood Transfus. 2014 Jan;12 Suppl 1(Suppl 1):s319-29. doi: 10.2450/2013.0246-12. Epub 2013 Dec 3.
6
Molecular basis of hemophilia.
Hematol Pathol. 1990;4(1):1-26.
7
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Br J Haematol. 2013 Jan;160(2):153-70. doi: 10.1111/bjh.12091. Epub 2012 Nov 15.
8
Gene therapy for haemophilia.
Baillieres Clin Haematol. 1996 Jun;9(2):305-17. doi: 10.1016/s0950-3536(96)80065-5.
9
Gene therapy for hemophilia: the clot thickens.
Hum Gene Ther. 2014 Nov;25(11):915-22. doi: 10.1089/hum.2014.2541.
10
Hemophilia Gene Therapy: Ready for Prime Time?
Hum Gene Ther. 2017 Nov;28(11):1013-1023. doi: 10.1089/hum.2017.116. Epub 2017 Aug 3.
引用本文的文献
1
From Circulating Biomarkers to Polymorphic Variants: A Narrative Review of Challenges in Thrombophilia Evaluation.
J Clin Med. 2025 May 15;14(10):3448. doi: 10.3390/jcm14103448.
2
Hemophilia B and gene therapy: a new chapter with etranacogene dezaparvovec.
Blood Adv. 2024 Apr 9;8(7):1796-1803. doi: 10.1182/bloodadvances.2023010511.
3
AAV gene therapy in companion dogs with severe hemophilia: Real-world long-term data on immunogenicity, efficacy, and quality of life.
Mol Ther Methods Clin Dev. 2024 Feb 2;32(1):101205. doi: 10.1016/j.omtm.2024.101205. eCollection 2024 Mar 14.
4
Humanization and functional characterization of enhanced coagulation factor IX variants identified through ancestral sequence reconstruction.
J Thromb Haemost. 2024 Mar;22(3):633-644. doi: 10.1016/j.jtha.2023.11.010. Epub 2023 Nov 26.
本文引用的文献
1
Safety and activity of an engineered, liver-tropic adeno-associated virus vector expressing a hyperactive Padua factor IX administered with prophylactic glucocorticoids in patients with haemophilia B: a single-centre, single-arm, phase 1, pilot trial.
Lancet Haematol. 2022 Jul;9(7):e504-e513. doi: 10.1016/S2352-3026(22)00113-2. Epub 2022 May 19.
2
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression.
Blood. 2021 Feb 11;137(6):763-774. doi: 10.1182/blood.2019004625.
3
Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates.
Mol Ther Methods Clin Dev. 2020 May 12;17:1129-1138. doi: 10.1016/j.omtm.2020.05.001. eCollection 2020 Jun 12.
4
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B.
Blood Adv. 2019 Nov 12;3(21):3241-3247. doi: 10.1182/bloodadvances.2019000811.
5
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant.
N Engl J Med. 2017 Dec 7;377(23):2215-2227. doi: 10.1056/NEJMoa1708538.
6
CpG-depleted adeno-associated virus vectors evade immune detection.
J Clin Invest. 2013 Jul;123(7):2994-3001. doi: 10.1172/JCI68205. Epub 2013 Jun 17.
7
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.
N Engl J Med. 2011 Dec 22;365(25):2357-65. doi: 10.1056/NEJMoa1108046. Epub 2011 Dec 10.
8
X-linked thrombophilia with a mutant factor IX (factor IX Padua).
N Engl J Med. 2009 Oct 22;361(17):1671-5. doi: 10.1056/NEJMoa0904377.
9
CD8(+) T-cell responses to adeno-associated virus capsid in humans.
Nat Med. 2007 Apr;13(4):419-22. doi: 10.1038/nm1549. Epub 2007 Mar 18.
Zotero 插件